Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells

BACKGROUND: Abelson (ABL) tyrosine kinase inhibitors (TKIs) are effective against chronic myeloid leukemia (CML); however, many patients develop resistance during ABL TKI therapy. Vitamin K2 (VK2) is a crucial fat-soluble vitamin used to activate hepatic coagulation factors and treat osteoporosis. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Okabe, Seiichi, Gotoh, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478393/
https://www.ncbi.nlm.nih.gov/pubmed/37670241
http://dx.doi.org/10.1186/s12885-023-11304-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478393/
https://www.ncbi.nlm.nih.gov/pubmed/37670241
http://dx.doi.org/10.1186/s12885-023-11304-4

Ejemplares similares